Abstract:
Disclosed are 6-amido-2-S-oxides of substituted 2-organothio-pen-2-em-3-carboxylic acids (I) which are useful as antibiotics and as intermediates in the synthesis of substituted pen-2-em-3-carboxylic acids: ##STR1## wherein: R 1  is H or acyl; R 2  is hydrogen or methoxyl; R 3  is alkyl having from 1-6 carbon atoms; phenylalkyl having 7-12 carbon atoms; and cycloalkyl having 3-6 carbon atoms; and R 4  is hydrogen, a removable protecting group or a pharmaceutically acceptable salt or ester moiety.

Description:
BACKGROUND OF THE INVENTION 
     This invention relates to certain substituted 6-amido-2-S-oxides of substituted 2-organothio-pen-2-em-3-carboxylic acids (I) which are useful as antibiotics: ##STR2## wherein: R 1  is H or acyl; R 2  is hydrogen or methoxy; R 3  is alkyl having from 1-6 carbon atoms; phenylalkyl having from 7-12 carbon atoms and cycloalkyl having 3-6 carbon atoms; and R 4  is hydrogen, a removable protecting group, or a pharmaceutically acceptable salt or ester moiety. 
     Suitable values for R 1  as acyl are disclosed in U.S. Pat. No. 4,226,866, issued Oct. 17, 1980, which is incorporated herein by reference. Generally, R 1  as acyl is chosen from those acyls known to be effective in the penicillin and cephalosporin art. Representative values for R 1  as acyl include: 
     IDENTIFICATION OF THE ACYL RADICAL R 1  OF STRUCTURE I 
     In the generic representation of the compounds of the present invention (I, above), the acyl radical represented by R 1  can, inter alia, be substituted or unsubstituted: aliphatic, aromatic or heterocyclic, araliphatic or heterocyclylaliphatic carboxylic acid radical, a substituted or unsubstituted: carbamyl radical or a carbothioic acid radical. One group of acyl radicals can be represented by the general formula: ##STR3## wherein X is O or S and R&#34; represents hydrogen; amino; substituted amino such as alkyl- and dialkylamino wherein the alkyl radical comprises 1 to about 6 carbon atoms; substituted or unsubstituted: straight or branched chain alkyl wherein the alkyl radical comprises 1 to about 6 carbon atoms; mercapto such as alkylthio, typically comprising 1 to 6 carbon atoms; arylthio, typically comprising 6 to 10 carbon atoms; hydroxy such as alkoxy, typically comprising 1 to 6 carbon atoms; aryloxy, typically comprising 6 to 10 carbon atoms; alkenyl, or alkynyl groups typically comprising 2 to 6 carbon atoms; aryl such as phenyl; aralkyl such as benzyl; cycloalkyl, typically comprising 3 to 6 carbon atoms; or a heteroaryl or heteroaralkyl group (mono- and bicyclic) wherein the alkyl moiety typically comprises 1 to 3 carbon atoms and the heterocyclic ring comprises typically 4-10 atoms and the hetero atom or atoms are selected from O, N and S; such above-listed groups can be unsubstituted or can be substituted by radicals such as OH, SH, SR° (R° is lower alkyl or aryl such as phenyl), alkyl or alkoxy groups having 1 to about 6 carbon atoms, halo such as Cl, Br, F and I, cyano, carboxy, sulfamino, carbamoyl, sulfonyl, azido, amino, substituted amino such as alkylamino including quaternary ammonium wherein the alkyl group comprises 1 to 6 carbon atoms, haloalkyl such as trifluoromethyl, carboxyalkyl, carbamoylalkyl, N-carbamoylalkyl, wherein the alkyl moiety of the foregoing four radicals comprises 1 to about 6 carbon atoms, amidino, guanidino, N-substituted guanidino, guanidino lower alkyl and the like. Representative examples of such acyl groups that might be mentioned are those wherein R&#34; is benzyl, p-hydroxybenzyl, 4-amino-4-carboxybutyl, methyl, cyanomethyl, 2-pentenyl, n-amyl, n-heptyl, ethyl, 3- or 4-nitrobenzyl, phenethyl, β,β-diphenylethyl, methyldiphenylmethyl, triphenylmethyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2,4,6-trimethoxyphenyl, 3,5-dimethyl-4-isoxazoyl, 3-butyl-5-methyl-4-isoxazolyl, 5-methyl-3-phenyl-4-isoxazolyl, 3-(2-chlorophenyl)-5-methyl-4-isoxazolyl, 3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl, D-4-amino-4-carboxybutyl, D-4-N-benzoylamino-4-carboxy-n-butyl, p-aminobenzyl, o-aminobenzyl, m-aminobenzyl, p-dimethylaminobenzyl, (3-pyridyl)methyl, 2-ethoxy-1-naphthyl, 3-carboxy-2-quinoxalinyl, 3-(2,6-dichlorophenyl)-5-(2-furyl)-4-isoxazolyl, 3-phenyl-4-isoxazolyl, 5-methyl-3-(4-guanidinophenyl)-4-isoxazolyl, 4-guanidinomethylphenyl, 4-guanidinomethylbenzyl, 4-guanidinobenzyl, 4-guanidinophenyl, 2,6-dimethoxy-4-guanidino, o-sulfobenzyl, p-carboxymethylbenzyl, p-carbamoylmethylbenzyl, m-fluorobenzyl, m-bromobenzyl, p-chlorobenzyl, p-methoxybenzyl, 1-naphthylmethyl, 3-isothiazolylmethyl, 4-isothiazolylmethyl, 5-isothiazolylmethyl, guanylthiomethyl, 4-pyridylmethyl, 5-isoxazolylmethyl, 4-methoxy-5-isoxazolylmethyl, 4-methyl-5-isoxazolylmethyl, 1-imidazolylmethyl, 1-imidazolylmethyl, 2-benzofuranylmethyl, 2-indolylmethyl, 2-phenylvinyl, 2-phenylethynyl, 1-aminocyclohexyl, 2- and 3-thienylaminomethyl, 2-(5-nitrofuranyl)vinyl, phenyl, o-methoxyphenyl, o-chlorophenyl, 1-phenylphenyl, p-aminoethylbenzyl, 1-(5-cyanotrizolyl)methyl, difluoromethyl, dichloromethyl, dibromomethyl, 1-(3-methylimidazolyl)methyl, 2- or 3-(5-carboxymethylthienyl)methyl, 2- or 3-(4-carbamoylthienyl)methyl, 2- or 3-(methoxythienyl)methyl, 2- or 3-(4-chlorothienyl)-methyl, 2- or 3-(5-sulfothienyl)methyl, 2- or 3-(5-carboxythienyl)methyl, 3-( 1,2,5-thiadiazolyl)methyl, 3-(4-methoxy-1,2,5-thiadiazolyl)methyl, 2-furylmethyl, 2-(5-nitrofuryl)methyl, 3-furylmethyl, 2-thienylmethyl, 3-thienylmethyl, tetrazolylmethyl benzamidinomethyl and cyclohexylamidinomethyl. 
     The acyl group can also be a radical of the formula: ##STR4## wherein X is O or S and n is 0-4, Z represents oxygen, sulfur, carbonyl or nitrogen and R&#34; is defined as above. Representative members of the substituent 
     
         --(CH.sub.2).sub.n ZR&#34; 
    
     that might be mentioned are allylthiomethyl, phenylthiomethyl, butylmercaptomethyl, α-chlorocrotylmercaptomethyl, phenoxymethyl, pehnoxyethyl, phenoxybutyl, phenoxybenzyl, diphenoxymethyl, dimethylmethoxymethyl, dimethylbutoxymethyl, dimethylphenoxymethyl, 4-tuanidinophenoxymethyl, 4-pyridylthiomethyl, p-(carboxymethyl)phenoxymethyl, p-(carboxymethyl)-phenylthiomethyl, 2-thiazolylthiomethyl, p-(sulfo)-phenoxymethyl, p-(carboxymethyl)-phenylthiomethyl, 2-pyrimidinylthiomethyl, phenethylthiomethyl, 1-(5,6,7,8-tetrahydronaphthyl)oxomethyl, N-methyl-4-pyridylthio, benzyloxy, methoxy, ethoxy, phenoxy, phenylthio, amino, methylamino, dimethylamino, pyridinium methyl, trimethylammoniummethyl, cyanomethylthiomethyl, trifluoromethylthiomethyl, 4-pyridylethyl, 4-pyridylpropyl, 4-pyridylbutyl, 3-imidazolylethyl, 3-imidazolylpropyl, 3-imidazolylbutyl, 1-pyrroloethyl, 1-pyrrolopropyl and 1-pyrrolobutyl. 
     Alternatively, the acyl group can be a radical of the formula: ##STR5## wherein R&#34; is defined as above and R&#34;&#39; is a radical such as amino, hydroxy, azido, carbamoyl, guanidino, amidino, acyloxy, halo, such as Cl, F, Br, I, sulfamino, tetrazolyl, sulfo, carboxy, carbalkoxy, phosphono and the like. Representative members of the substituent: ##STR6## that might be mentioned are α-aminobenzyl, α-amino-(2-thienyl)methyl, α-(methylamino)benzyl, α-aminomethylmercaptopropyl, α-amino-3- or 4-chlorobenzyl, α-amino-3- or 4-hydroxybenzyl, α-amino-2,4-dichlorobenzyl, α-amino-3,4-dichlorobenzyl, D(-)-α-hydroxybenzyl, α-carboxybenzyl, α-amino(3-thienyl)-methyl D-(-)-α-amino-3-chloro-4-hydroxybenzyl, α-amino(cyclohexyl)methyl, α-(5-tetrazolyl)-benzyl, 2-thienyl-carboxymethyl, 3-thienyl-carboxymethyl, 2-furylcarboxymethyl, 3-furyl-carboxymethyl, α-sulfaminobenzyl, 3-thienyl-sulfaminomethyl, α-(N-methylsulfamino)-benzyl, D(-)-2-thienyl-guanidinomethyl, D-(-)-α-guanidinobenzyl, α-guanylureidobenzyl, α-hydroxybenzyl, α-azidobenzyl, α-fluorobenzyl, 4-(5-methoxy-1,3-oxadiazolyl)-aminomethyl, 4-(5-methoxy-1,3-oxadiazolyl)-hydroxymethyl, 4-(5-methoxy-1,3-sulfadiazolyl)-hydroxymethyl, 4-(5-chlorothienyl)aminomethyl, 2-(5-chlorothienyl)-hydroxymethyl, 2-(5-chlorothienyl)-carboxy-methyl, 3-(1,2-thiazolyl)aminomethyl, 3-(1,2-thiazolyl)-hydroxymethyl, 3-(1,2-thiazolyl)carboxymethyl, 2-(1,4-thiazolyl)aminomethyl, 2-(1,4-thiazolyl)-hydroxymethyl, 2-(1,4-thiazolyl)carboxymethyl, 2-benzothienylaminomethyl, 2-benzothienylhydroxymethyl, 2-benzothienylcarboxymethyl, α-sulfobenzyl, α-phosphonobenzyl, α-diethylphosphono and α-monoethylphosphono. Further acyl radicals of interest in this class when X=oxygen are: ##STR7## wherein R 3&#39;  and R 4&#39;  are as defined below. R 3&#39;  represents hydrogen, halo, such as chloro, fluoro, bromo, iodo, amino, guanidino, phosphono, hydroxy, tetrazolyl, carboxy, sulfo, or sulfamino and R 4  represents phenyl, substituted phenyl, a mono- or bicyclic heterocyclyl containing one or more oxygen, sulfur or nitrogen atoms in the ring, such as furyl, quinoxyalyl, thienyl, quinolyl, quinazolyl, thiazolyl, isothiazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl and the like substituted heterocycles, phenylthio, phenyloxy, lower alkyl of 1-6 carbon atoms, heterocyclic or substituted heterocyclic thio groups; or cyano. The substituents on the moieties, R 3&#39;  and R 4&#39; , can be halo, carboxymethyl, guanidino, guanidinomethyl, carboxamidomethyl, aminoethyl, nitro, methoxy or methyl. When R 3&#39;  is selected from the group consisting of hydrogen, hydroxy, amino or carboxy and R 4&#39;  is selected from the group consisting of phenyl, or a 5- or 6-membered heterocyclic ring having one or two sulfur, oxygen or nitrogen hetero atom such as tetrazolyl, thienyl, furyl and phenyl, the following acyl radicals are representative: phenylacetyl, 3-bromophenylacetyl, p-aminomethylphenylacetyl, 4-carboxymethylphenylacetyl, 4-carboxyamidomethylphenylacetyl, 2-furylacetyl, 5-nitro-2-furylacetyl, 3-furylacetyl, 2-thienylacetyl, 5-chloro-2-thienylacetyl, 5-methoxy-2-thienylacetyl, α-guanidino-2-thienylacetyl, 3-thienylacetyl, 2-(4-methylthienyl)-acetyl, 3-isothiazolylacetyl, 4-methoxy-3-isothiazolylacetyl, 4-isothiazolylacetyl, 3-methyl-4-isothiazolylacetyl, 5-isothiazolylacetyl, 3-chloro-5-isothiazolylacetyl, 3-methyl-1,2,5-oxadiazolylacetyl, 1,2,5-thiadiazolyl-4-acetyl, 3-methyl-1,2,5-thiadiazolylacetyl, 3-chloro-1,2,5-thiadiazolylacetyl, 3-methoxy-1,2,5-thiadiazolylacetyl, phenylthioacetyl, 4-pyridylthioacetyl, cyanoacetyl, 1-tetrazolylacetyl, α-fluorophenylacetyl, D-phenylglycyl, 4-hydroxy-D-phenylglycyl, 2-thienylglycyl, 3-thienylglycyl, phenylmalonyl, 3-chlorophenylmalonyl, 2-thienylmalonyl, 3-thienylmalonyl, aphosphonophenylacetyl, α-amino cyclohexadienylacetyl, α-sulfaminophenylacetyl, α-hydroxyphenylacetyl, α-tetrazolylphenylacetyl and α-sulfophenylacetyl. 
     Acyls (R 1 , Structure I) of the following definition are also preferred: ##STR8## X=0, NOR 9  ; R 9  =H, alkyl having 1-6 carbon atoms. 
     Compounds I are also useful in the synthesis of penem antibiotics of structure II via reaction with reagent HSR 8  : ##STR9## wherein R 8  is an organo radical such as those disclosed in U.S. Pat. No. 4,194,047 (issued Mar. 18, 1980), and European Patent Application No. 80102076.9 (Publication Number 0017992), which documents are incorporated herein to the extent that they define the moiety of the 2-substituent, R 8  ; for example, R 8  may be: phenyl, CH 2  CH 2  NHCH═NH, CH 2  CH 2  NHC(CH 3 )═NH, or t-butyl. The basic, analogous process I to II, above, is disclosed and claimed in concurrently filed, commonly assigned U.S. patent application Ser. No. 353,454, filed Mar. 1, 1982, which application, to the extent that it defines the alternative intermediate utility of the compounds I of the present invention, is incorporated herein by reference; the incorporated application is directed to 6-substituents other than amido, and in this sense is offered in analogy to the above process utility I to II. 
     The compounds of the present invention are prepared by oxidation of the corresponding 2-organothio penem: ##STR10## wherein relative to compound Ia, substituents R 1 , R 2 , R 3  and R 4  are as previously defined. It should be noted that the genus defined by Ia is known. See for example: U.S. Pat. No. 4,215,124 issued July 29, 1980 which patent to the extent it defines Ia is incorporated herein by reference. 
     Without regard to the chirality of other centers, and with reference only to the chirality about the sulfur atom, it should be noted that compounds I exist as the sulfoxide diastereomers Ib and Ic: ##STR11## which can be separated by conventional techniques if desired, but the displacement reaction (I to II, above) operates without distinction upon the mixture I. Thus, for convenience, the sulfoxide mixture will be depicted by the planar structure I, above. 
     This invention also relates to the carboxyl derivatives of I which are antibiotics and which may be represented by the following generic structure (I): ##STR12## wherein X&#39; is oxygen, sulphur or NR&#39; (R&#39;=H or lower alkyl having 1-6 carbon atoms); and R 4  is hydrogen, or, inter alia, is representatively selected to provide the pharmaceutically acceptable salt, ester, anhydride (R 4  is acyl), and amide moieties known in the bicyclic β-lactam antibiotic art; R 4  may also be a removable blocking group; the definition of R 4  is given in greater detail below. 
     This invention also relates to processes for the preparation of such compounds (I); pharmaceutical compositions comprising such compounds; and to methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated. 
     There is a continuing need for new antibiotics. For unfortunately, there is no static effectiveness of any given antibiotic because continued wide scale usage selectively gives rise to resistant strains of pathogens. In addition, the known antibiotics suffer from the disadvantage of being effective only against certain types of microorganisms. Accordingly, the search for new antibiotics continues. 
     Thus, it is an object of the present invention to provide a novel class of antibiotics which are useful in animal and human therapy and in inanimate systems. These antibiotics are active against a broad range of pathogens which representatively include both Gram positive bacteria such as S. aureus, Strep. pyogenes, and B. subtilis, and Gram negative bacteria such as E. coli, Pseudomonas, Proteus morganii, Serratia, and Klebsiella. Further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their nontoxic pharmaceutically acceptable salts; pharmaceutical compositions comprising such antibiotics; and to provide methods of treatment comprising administering such antibiotics and compositions when an antibiotic effect is indicated. 
     DETAILED DESCRIPTION OF THE INVENTION 
     The compounds of the present invention (I, above) are conveniently prepared by the following scheme: ##STR13## Relative to the above reaction scheme, there is no undue criticality as to the precise identity of the oxidizing agent. Suitable oxidizing agents include peracids such as m-chloroperbenzoic acid and peracetic acid. Other representative oxidizing agents include potassium permanganate, hydrogen peroxide, sodium meta periodate, t-butyl hydrogen peroxide, dichloro iodobenzene, sulfuryl chloride, wet silica gel, sodium hypochlorite, and ozone, for example. Typically, 1.0 eq. to a slight excess of oxidizing reagent is employed. There is no criticality as to reaction solvent--any solvent being acceptable which is inert or substantially inert during the course of reaction and which effectively solubilizes the starting material Ia. Representative examples of suitable solvents for the oxidation include tetrahydrofuran, methylenechloride, dimethylformamide, methanol and water. Typically, the reaction is conducted at a temperature of from about -78° to 50° C., for from a few minutes to several hours. As mentioned above, starting materials Ia are known. 
     As noted above, the compounds of the present invention may also generally be represented by the following structural formula: ##STR14## wherein X&#39; is oxygen, sulfur or NR&#39; (R&#39; is hydrogen or loweralkyl having from 1 to 6 carbon atoms); and R 4  is hydrogen, or, inter alia, is representatively selected to provide the pharmaceutically acceptable salt, ester, anhydride (R 4  is acyl), and amide moieties known in the bicyclic β-lactam antibiotic art; R 4  may also be a readily removable blocking group. 
     IDENTIFICATION OF THE RADICAL --COX&#39;R 4   
     In the generic representation of the compounds of the present invention (I, above), the radical represented by --COX&#39;R 4  is, inter alia, --COOH (X&#39; is oxygen and R 4  is hydrogen) and all radicals known to be effective as pharmaceutically acceptable ester, anhydride (R 4  is acyl) and amide radicals in the bicyclic β-lactam antibiotic art, such as the cephalosporins and penicillins and nuclear analogues thereof. 
     Suitable, but representative, blocking esters R 4  (X&#39;=O) include those selected from the following list which is representative: 
     (i) R 4  =CR a  R b  R c  wherein at least one of R a , R b , and R c  is an electron-donor, e.g., p-methoxyphenyl. The remaining R a , R b  and R c  groups may be hydrogen or organic substituting groups. Suitable ester groups of this type include p-methoxybenzyloxycarbonyl. 
     (ii) R 4  =CR a  R b  R c  wherein at least one of R a , R b  and R c  is an electron-attracting group, e.g., p-nitrophenyl, trichloromethyl, and o-nitrophenyl. Suitable esters of this type include p-nitrobenzyloxycarbonyl, and 2,2,2-trichloroethoxycarbonyl. 
     (iii) R 4  =CR a  R b  R c  wherein at least two of R a , R b  and R c  are hydrocarbon such as alkyl, e.g., methyl or ethyl, or aryl, e.g., phenyl and the remaining R a , R b  and R c  group, if there is one, is hydrogen. Suitable esters of this type include t-butyloxycarbonyl, diphenylmethoxycarbonyl and triphenylmethoxycarbonyl. 
     Silyl esters. This category of blocking groups, may conveniently be prepared from a halosilane of the formula: R 3   4 ° SiX° wherein X° is a halogen such as chloro or bromo and R 4&#39;  is alkyl, having 1-6 carbon atoms, phenyl, or phenylalkyl. 
     Pharmaceutically acceptable carboxyl derivatives of the present invention are those derived by reacting I with alcohols, acylating reagents and the like. For example, esters and amides of interest are the above-listed starting materials and final products having the --COX&#39;R 4  group at the 3-position; wherein X&#39; is oxygen, sulfur or NR&#39; (R&#39; is H or R 4 ), and R 4  is alkyl having 1-6 carbon atoms, straight or branched, such as methyl, ethyl, t-butyl, and the like; carbonylmethyl, including phenacyl; aminoalkyl including 2-methylaminoethyl, 2-diethylaminoethyl; alkanoyloxyalkyl wherein the alkanoyloxy portion is straight or branched and has 1-6 carbon atoms and the alkyl portion has 1-6 carbon atoms, such as pivaloyloxymethyl; haloalkyl wherein halo is chloro, and the alkyl portion is straight or branched having 1-6 carbon atoms, e.g., 2,2,2-trichloroethyl; alkenyl having 1-4 carbon atoms, such as 2-propenyl, 3-butenyl, and 4-butenyl; aralkyl and lower alkoxyl- and nitro-substituted aralkyl such as benzyl, benzhydryl, o-nitrobenzyl, p-methoxybenzyl, and p-nitrobenzyl; phthalidyl; benzyloxyalkyl having 8-10 carbon atoms, such as benzyloxymethyl, and (4-nitro) benzyloxymethyl. 
     In addition to the esters (and thio esters) listed above, amides are also embraced by the present invention, i.e., wherein X&#39; is the --NR&#39;-- group. Representative of such amides are those wherein R&#39; is selected from the group consisting of hydrogen and alkyl such as methyl and ethyl. 
     The most preferred --COX&#39;R 4  radicals of the present invention are those wherein (relative to Structure I above), X&#39; is oxygen and R 4  is hydrogen; loweralkyl having 1-4 carbon atoms; lower alkenyl such as 3-methylbutenyl, allyl, 2,2,2-trichloroethyl, 4-butenyl and the like; benzyl and substituted benzyl such as o-nitrobenzyl, p-nitrobenzyl; pivaloyloxymethyl, 3-phthalidyl; phenacyl, acetonyl; and triorganosilyl, such as trimethylsilyl. 
     PREFERRED VALUES FOR R 1  AND R 2   
     In the generic structure I, above, the preferred values for R 1  include hydrogen and the above-recited acyls; the most preferred values for R 2  are hydrogen and methoxyl. 
     The compounds of the present invention (I) are valuable antibiotics active against various Gram-positive and Gram-negative bacteria and accordingly find utility in human and veterinary medicine. Representative pathogens which are sensitive to antibiotics I include: Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Bacillus subtilis, Salmonella typhosa, Psuedomonas and Bacterium proteus. The antibacterials of the invention are not limited to utility as medicaments; they may be used in all manner of industry, for example: additives to animal feed, preservation of food, disinfectants, and in other industrial systems where control of bacterial growth is desired. For example, they may be employed in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution in order to destroy or inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example in waterbased paints and in the white water of paper mills to inhibit the growth of harmful bacteria. 
     The products of this invention may be used in any of a variety of pharmaceutical preparations. They may be employed in capsule, powder form, in liquid solution, or in suspension. They may be administered by a variety of means; those of prinicipal interest include: orally, topically or parenterally by injection (intravenously or intramuscularly). 
     Such tablets and capsules, designed for oral administration, may be in unit dosage form, and may contain conventional excipients, such as binding agents, for example, syrup acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example, lactose, sugar, cornstarch, calcium phosphate, sorbitol, or glycerine; lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato starch, acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of aqueous or oily suspensions, or solutions, or they may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, or carboxymethyl cellulose. Suppositories will contain conventional suppository bases, such as cocoa butter or other glycerides. 
     Compositions for injection, the preferred route of delivery, may be prepared in unit dosage form in ampules, or in multidose containers. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents. Alternatively, the active ingredient may be in powder form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile water. 
     The compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of liquid sprays or inhalants, lozenges, or throat paints. For medication of the eyes or ears, the preparation may be presented in liquid or semi-solid form. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, or powders. 
     The dosage to be administered depends to a large extent upon the condition and size of the subject being treated as well as the route and frequency of administration--the parenteral route by injection being preferred for generalized infections. Such matters, however, are left to the routine discretion of the therapist according to principles of treatment well known in the antibiotic art. In general, a daily dosage consists of from about 5 to about 600 mg of active ingredient per kg. of body weight of the subject in one or more treatments per day. A preferred daily dosage for adult humans lies in the range of from about 10 to 240 mg. of active ingredient per kg. of body weight. Another factor influencing the precise dosage regimen, apart from the nature of the infection and peculiar identity of the individual being treated, is the molecular weight of the chosen species of this invention (I). 
     The compositions for human delivery per unit dosage, whether liquid or solid, may contain from 0.1% to 99% of active material, the preferred range being from about 10-60%. The composition will generally contain from about 15 mg. to about 1500 mg. of the active ingredient; however, in general, it is preferable to employ a dosage amount in the range of from about 250 mg to 1000 mg. In parenteral administration, the unit dosage is usually the pure compound I in sterile water solution or in the form of a soluble powder intended for solution. 
     In the foregoing word description, it is to be understood that there is considerable latitude in selection of precise reaction parameters. Suggestion of this latitude and its breadth is generally indicated by the enumeration of equivalent solvent systems, temperature ranges, protecting groups, and range of identities of involved reagents. 
    
    
     The following examples recite a precise scheme of synthesis. It is to be understood that the purpose of this recitation is to further illustrate the invention and not to impose any limitation. Temperature is in °C. 
     EXAMPLE 1 ##STR15## 
     To a stirred solution of 11.3 mg. of penem 1 in 1 ml. of methylene chloride at 0° C. in an ice-H 2  O bath is added 7.2 mg. (0.035 mmol) of 85% m-chloroperbenzoic acid. The mixture is stirred at 0° C. under an atmosphere of nitrogen for 1.0 hour after which time an excess of basic resin (Amberlyst-21) is added and stirring continued for 5 minutes. The resin is removed by filtration and the filtrate is purified directly by plate layer chromatography (PLC) using CH 2  Cl 2  --EtOAc (1:1) as the eluant, to provide sulfoxides 2. 
     EXAMPLE 2 ##STR16## 
     A solution of 85% m-chloroperoxy benzoic acid (53 mg, 0.26 mmol) in CH 2  Cl 2  (1 ml) is added dropwise over a few minutes to an ice-cold, stirring solution of penem 1 (0.25 mmol) in anhydrous THF (2 ml). The resulting solution is stirred an additional 30 minutes at 0°, then diluted with EtOAc and washed with H 2  O, 5% aqueous NaHCO 3 , H 2  O, and brine. The organic phase is dried with MgSO 4 , filtered, and evaporated in vacuo to provide compound 2 as a mixture of sulfoxide isomers. 
     EXAMPLE 3 ##STR17## 
     A solution of 1 (50 mg) in THF (9 ml) is diluted with EtOH (4.5 ml) and H 2  O (7.0 ml) containing NaHCO 3  (10.6 mg). The resulting solution is added to a pre-reduced mixture of 10% Pd/C (100 mg) in EtOH (4.5 ml) and the resulting mixture is rapidly stirred under a H 2  atmosphere for 2 hours. The mixture is filtered to remove the catalyst which is washed with H 2  O (2×25 ml). The combined filtrate is extracted with Et 2  O (2×50 ml) concentrated under vacuum to ca. 10 ml volume, and lyophilized to yield compound 2. 
     EXAMPLE 4 
     Preparation of Pharmaceutical Compositions 
     One such unit dosage form is prepared by mixing 120 mg of compound A: ##STR18## with 20 mg of lactose and 5 mg of magnesium stearate and placing the 145 mg mixture into a No. 3 gelatin capsule. Similarly, by employing more of the active ingredient and less lactose, other dosage forms can be put up in No. 3 gelatin capsules, and, should it be necessary to mix more than 145 mg of ingredients together, larger capsules such as compressed tablets and pills can be prepared. The following examples are illustrative of the preparation of pharmaceutical formulations: 
     
         ______________________________________TABLET              PER TABLET______________________________________Compound A          125        mg.Cornstarch, U.S.P.  6          mg.Dicalcium Phosphate 192        mg.Lactose, U.S.P.     190        mg.Magnesium Stearate  Balance/800                          mg.______________________________________ 
    
     The active ingredient is blended with dicalcium phosphate, lactose and about half of the cornstarch. The mixture is then granulated with 15% cornstarch paste (6 mg) and rough-screened. It is dried at 45° C. and screened again through No. 16  screens. The balance of the cornstarch and magnesium stearate is added and the mixture is compressed into tablets, approximately 0.5 inch in diameter each weighing 800 mg. 
     
         ______________________________________                PER TABLET______________________________________PARENTERAL SOLUTIONAmpoule:Compound A             500     mg.Diluent: Sterile Water for Injection                  2       cc.OPHTHALMIC SOLUTIONCompound A             100     mg.Hydropropylmethyl Cellulose                  5       mg.Sterile Water to       1       ml.OTIC SOLUTIONCompound A             100     mg.Benzalkonium chloride  0.1     mg.Sterile Water to       1       ml.TOPICAL OINTMENTCompound A             100     mg.Polyethylene Glycol 4000 U.S.P.                  400     mg.Polyethylene Glycol 400 U.S.P.                  1.0     gram______________________________________